These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 31831255)

  • 1. Sjögren's syndrome: Old and new therapeutic targets.
    Mavragani CP; Moutsopoulos HM
    J Autoimmun; 2020 Jun; 110():102364. PubMed ID: 31831255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
    Blokland SLM; Hillen MR; Wichers CGK; Zimmermann M; Kruize AA; Radstake TRDJ; Broen JCA; van Roon JAG
    RMD Open; 2019; 5(1):e000701. PubMed ID: 30713717
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
    J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and New Strategies for Primary Sjögren's Syndrome.
    Mavragani CP
    Annu Rev Med; 2017 Jan; 68():331-343. PubMed ID: 28099084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.
    Srivastava A; Makarenkova HP
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the understanding and treatment of systemic complications in Sjögren's syndrome.
    Brito-Zerón P; Ramos-Casals M;
    Curr Opin Rheumatol; 2014 Sep; 26(5):520-7. PubMed ID: 25050925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One year in review 2016: Sjögren's syndrome.
    Ferro F; Vagelli R; Bruni C; Cafaro G; Marcucci E; Bartoloni E; Baldini C
    Clin Exp Rheumatol; 2016; 34(2):161-71. PubMed ID: 27095672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation in Sjögren's syndrome: Cause or consequence?
    Rodrigues AR; Soares R
    Autoimmunity; 2017 May; 50(3):141-150. PubMed ID: 28276715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the diagnosis and treatment of Sjogren's syndrome.
    Chen X; Wu H; Wei W
    Clin Rheumatol; 2018 Jul; 37(7):1743-1749. PubMed ID: 29804149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic treatment in Sjögren's syndrome.
    Sada PR; Isenberg D; Ciurtin C
    Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of Sjögren's syndrome and therapeutic consequences.
    Mariette X; Gottenberg JE
    Curr Opin Rheumatol; 2010 Sep; 22(5):471-7. PubMed ID: 20671520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting the role of T cells in the pathogenesis of Sjögren's syndrome for therapeutic treatment.
    An Q; Zhao J; Zhu X; Yang B; Wu Z; Su Y; Zhang L; Xu K; Ma D
    Front Immunol; 2022; 13():995895. PubMed ID: 36389806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of Sjögren's syndrome.
    García-Carrasco M; Fuentes-Alexandro S; Escárcega RO; Salgado G; Riebeling C; Cervera R
    Arch Med Res; 2006 Nov; 37(8):921-32. PubMed ID: 17045106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.
    Jang SI; Tandon M; Teos L; Zheng C; Warner BM; Alevizos I
    EBioMedicine; 2019 Oct; 48():526-538. PubMed ID: 31597594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Insights in Microbiome Shifts in Sjogren's Syndrome and Possible Therapeutic Interventions.
    Tsigalou C; Stavropoulou E; Bezirtzoglou E
    Front Immunol; 2018; 9():1106. PubMed ID: 29881381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of autophagy impairment inhibits pathology in the NOD.H-2h4 mouse model of primary Sjögren's syndrome.
    Voynova E; Lefebvre F; Qadri A; Muller S
    J Autoimmun; 2020 Mar; 108():102418. PubMed ID: 32029330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.
    Hansen A; Lipsky PE; Dörner T
    Curr Opin Rheumatol; 2005 Sep; 17(5):558-65. PubMed ID: 16093833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [B lymphocytes in Sjögren's syndrome].
    Pers JO; Le Pottier L; Devauchelle V; Saraux A; Youinou P
    Rev Med Interne; 2008 Dec; 29(12):1000-6. PubMed ID: 18403061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging biological therapies in primary Sjogren's syndrome.
    Ramos-Casals M; Brito-Zerón P
    Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.